 | Up a level |
Greenhalgh, Janette 
ORCID: 0000-0003-4812-1904, Bagust, Adrian ORCID: 0000-0002-2142-5767, Boland, Angela ORCID: 0000-0002-5435-8644, Dwan, Kerry, Beale, Sophie ORCID: 0000-0003-0164-103X, Hockenhull, Juliet ORCID: 0000-0002-2026-3778, Proudlove, Christine, Dundar, Yenal, Richardson, Marty ORCID: 0000-0002-7097-8704, Dickson, Rumona ORCID: 0000-0003-1416-0913 et al (show 2 more authors)
(2015)
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
HEALTH TECHNOLOGY ASSESSMENT, 19 (47).
I-133.
Nicholson, Amanda, Mahon, James, Boland, Angela ORCID: 0000-0002-5435-8644, Beale, Sophie ORCID: 0000-0003-0164-103X, Dwan, Kerry, Fleeman, Nigel ORCID: 0000-0002-4637-9779, Hockenhull, Juliet ORCID: 0000-0002-2026-3778 and Dundar, Yenal
(2015)
The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.
Health Technology Assessment, 19 (87).
1-+.